The AGT M235T TT polymorphism is associated with reduced birth weight (TT: 3288 g versus TM R MM: 3435 g, P < 0.05). Furthermore, newborns with a high percentage of fTGH (>6.5%) are more likely to have the TT genotype than those with normal fTGH (< -6.5%, P < 0.05). With higher cutoffs for fTGH, the significance increases to P less than 0.005. No association was seen between these parameters and the fetal angiotensin-converting enzyme insertion/deletion phenotype.
New evidence for the fetal insulin hypothesis: fetal angiotensinogen M235T polymorphism is associated with birth weight and elevated fetal total glycated hemoglobin at birth Background Low birth weight is associated with an increased risk of cardiovascular events in later life. Insulin resistance is a key finding in adult patients with cardiovascular diseases. The neonatal phenotype of an individual with insulin resistance might be low birth weight, as insulin influences fetal growth. The renin-angiotensinaldosterone system has been associated with cardiovascular disease and insulin resistance. We analyzed whether fetal polymorphisms of the angiotensinogen (AGT) and angiotensin-converting enzyme genes influence birth weight and/or fetal total glycated hemoglobin (fTGH), a surrogate parameter of fetal insulin resistance at birth.
Method In 1132 white women delivering singletons, neonatal umbilical blood samples and clinical data of the mothers and newborns were obtained. Newborns were genotyped with respect to the AGT M235T and angiotensinconverting enzyme insertion/deletion polymorphism.
Introduction
Low birth weight is an independent risk factor for cardiovascular disease and glucose intolerance in later life. This was first elucidated from the geographical distribution of heart disease in Great Britain [1] . Several epidemiological studies in Europe, the United States and India have thereafter confirmed these findings [2] [3] [4] [5] [6] [7] [8] .
It was suggested that coronary artery disease (CAD), glucose intolerance and hypertension arise from maternal malnutrition during pregnancy and early infancy through mechanisms of developmental plasticity [1] . Especially when occurring during critical time windows of development, fetal programming can lead to irreversible morphological and functional changes and higher susceptibility to disease later in life [9, 10] . It has been proposed that this effect is strongest when a 'mismatch' between the intrauterine and postnatal nutritional conditions occurs. Mechanisms discussed to explain the observed changes include epigenetic modification of DNA, changes in tissue differentiation and shifts in homeostatic control mechanisms [11] . This concept was further developed by our group, giving rise to the advanced fetal programming hypothesis. It states that maternal genetic polymorphisms influence the development of low birth weight entailing the aforementioned consequences [12] .
The renin-angiotensin-aldosterone system (RAAS) is known to be involved in fetal and placental development [13] . Angiotensinogen (AGT), renin, angiotensin-converting enzyme (ACE) and angiotensin II (AGT II)-AT 1 receptor expression have been detected in first trimester deciduas and in and around spiral arteries [14] . During normal pregnancy, the RAAS is stimulated and plasma renin activity, AGT, AGT II and aldosterone levels increase in both fetal and maternal parts of the placenta [15] . Data from animal experiments show that the RAAS is one of the physiologic systems modulated by mechanisms of fetal programming [16] [17] [18] [19] .
The common M235T variant of the AGT gene encodes threonine instead of methionine at residue 235 in exon 2 and is associated with raised plasma AGT levels in nonpregnant individuals [20] . It was reported that the T allele may be related to abnormal pregnancy-induced spiral artery remodeling early in pregnancy and may be involved in altered AGT expression [21] . Effects were most strongly pronounced in the TT genotype, suggesting a T-recessive heredity [22, 23] . AGT II is a potent vasoconstrictor and, acting as a growth factor, leads to medial hyperplasia of blood vessels. It is therefore considered an important factor of placentation. ACE, another important component of the RAAS, converts angiotensin I (AGT I) to AGT II. A common insertion/deletion (I/D) polymorphism in ACE gene in intron 16 is associated with plasma ACE activity, with the DD genotype being related to the highest plasma activity [24] . ACE activity has been shown to be higher in preterm infants and a D-recessive inheritance pattern is most likely [25, 26] .
With the RAAS being involved in the regulation of placentation and uteroplacental blood flow, it is plausible to suggest that RAAS abnormalities may be partly responsible for low birth weight [14, 15, 27, 28] . They may also play an important role in the pathogenesis of CAD and the formation of diabetes later in life [29, 30] . As the placental vascular bed is of maternal and fetal origin, the investigation of maternal and fetal genetic components of the RAAS is of interest. In a previous analysis of our cohort, we could show that maternal RAAS polymorphisms do not influence fetal growth and birth weight in the sense of the advanced fetal programming hypothesis [31] . Low birth weight and pregnancy outcome could nevertheless also reflect phenotypes of the RAAS genotype in the fetus [32, 33] .
Resistance to insulin as an intrauterine growth factor may lead primarily to lower birth weight as very first phenotypic manifestation of this insulin-resistant genotype. As a consequence, low birth weight seen in very early life might be the phenotypic manifestation of genes responsible for insulin resistance and higher risk for CAD in later life [34, 35] .
We therefore analyzed whether low birth weight is related to the I/D ACE polymorphism or the M235T AGT variant in newborns.
Methods

Individuals and data collection
All women delivering at Charité University Hospital, Germany, between January 2000 and September 2001 (n ¼ 1446) were invited to participate in our study, which received approval from the local ethics committee. Only white women with singleton pregnancies were considered (n ¼ 1301), of which 95.5% gave informed written consent (n ¼ 1242). All participating individuals underwent physical examination by a trained physician during pregnancy including an interview asking for example for family history of diabetes [does at least one family member (sisters, brother's parents or grandparents) have diabetes]. Maternal and neonatal (umbilical) venous blood samples were obtained immediately after delivery for genotype analysis and a structured interview was performed. We could obtain blood samples from the newborns in 93% of all cases (n ¼ 1132). Information from the maternity card (Mutterpass) were also extracted and incorporated into the study. Blood pressure was measured at all follow-up visits by a physician or trained nurse via the auscultatory method using a mercury or aneroid sphygmomanometer, and women were classified according to the definition of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy [36] .
Genetic analysis
Genomic DNA was isolated from peripheral white blood cells [37] . Genotyping was performed as described previously [38] .
Angiotensinogen M235T polymorphism
The T-C transition at nucleotide 704 in exon 2 produces a half site for the AspI restriction enzyme (Roche, Mannheim, Germany). Introduction of the corresponding half site is achieved by using primer with two mismatches. These are located at positions four and five from its 30 end and do not interfere with elongation: 5 0 -CAGGGT GCTGTCCACACTGGACCCC-3 0 and 5 0 -CCGTTT GTGCAGGCCTGGCTCTCT-3 0 . PCR yields a product of 165 base pairs (bp). In the presence of C at position 704, cleavage by AspI generates a fragment of 141 bp.
Angiotensin-converting enzyme insertion/deletion polymorphism DNA fragments were amplified using the following primers: 5 0 -GCCCTGCAGGTGTCTGCAGCATGT-3 0 and 5 0 -GGATGGCTCTCCCCGCCTTGTCTC-3 0 . PCR yields products of 319 and 597 bp for the D and I alleles, respectively. All samples yielding amplification products of the D allele exclusively (and therefore potentially typed as DD) were subjected to a second independent amplification using primers specific for the sequence insert to intron 16 of the I allele with the following primers: 5 0 -TGGGACCACAGCGCCCGCCACTAC-3 0 and 5 0 -TCGCCAGCC CTCCCATGCCCATAA-3 0 .
PCR yields an amplification product of 355 bp only in the presence of an I allele. Only matching results from separate blinded double determinations were accepted.
Analysis of fetal total glycated hemoglobin
Fetal blood was analyzed with the HPLC-based Variant Total Glycated Hemoglobin testing system (Bio-Rad, Hercules, California, USA) as described before [34] .
The test works independently of the hemoglobin type and is thus able to quantify glycosylation of fetal and adult hemoglobin. Briefly, the system separates glycosylated from nonglycosylated hemoglobin by boronateaffinity chromatography. The separated hemoglobins pass through a filter photometer in which changes of absorbance are measured at 415 nm. A secondary filter at 690 nm corrects for matrix effects caused by mixing buffers of different ionic strength and a calibrator is analyzed with each run. No interference with labile glycosylated hemoglobins, lipemia, bilirubin, temperature fluctuations or age-related degradation is observed. The system has been certified by the US National Glycohemoglobin Standardization Program.
Statistical analysis
Data were analyzed using SPSS version 17 (SPSS, Inc., Chicago, Illinois, USA). Analysis for independence of categorical or dichotomous variables was performed using Pearson's x 2 or Fisher's exact test, whatever applicable. Comparison of continuous variables between two groups was done with Student's t test, if variables were approximately normally distributed that was tested by Kolmogorow-Smirnov test, otherwise with Wilcoxon-MannWhitney test. When comparing means of birth weight and gestational age between groups, P-values were adjusted for gestational age and birth weight, respectively, as well as maternal diabetes and hypertension during pregnancy, maternal age, BMI, smoking and fetal sex in an analysis of covariance (ANCOVA). Categorical variables [low versus high fetal total glycated hemoglobin (fTGH), low versus normal birth weight, weight in relation to gestational age [39] ] were adjusted for confounders using binary or multinomial logistic regression analysis. All tests were two-sided and P-values less than 0.05 were considered significant.
Results
The descriptive characteristics of the study population are shown in Table 1 . A total of 6.2% of all newborns had a birth weight below 2500 g (low birth weight). The frequency of maternal smoking during pregnancy was 33.3% in pregnancies with low birth weight outcome and 17.1% in pregnancies with normal birth weight outcome. Of all mothers who smoked during pregnancy, 10.8% gave birth to a low birth weight baby, whereas only 4.8% of nonsmoking mothers did so (P adj < 0.05). The genotype distributions of the AGT M235T and ACE I/D polymorphisms can be seen in Table 2 .
Literature suggests a T-recessive heredity for the M235T polymorphisms and similarly a D-recessive one for the I/D polymorphism. We therefore tested for statistical differences comparing the groups 'TT' and 'MM þ MT', MT', as well as 'DD' and 'ID þ DD'.
After adjusting for confounders, newborns homozygous for the AGT T allele have a significantly lower birth weight compared with newborns not homozygous for the AGT T allele (3288 g versus 3435 g, P adj < 0.05; Fig. 1 ). Additionally, 10.1% of newborns with the TT genotype are of low birth weight as compared with 4.9% newborns with either MM or MT genotype. Of all newborns with low birth weight, 25.5% are TT-homozygous, compared with newborns with a birth weight greater than 2500 g of which only 13.5% carry two T-alleles (P adj < 0.01, Fig. 2a) . A total of 13.5% of all TT-homozygous newborns are small for gestational age (SGA, as defined by below the 10th percentile of birth weight for gestational age) and 6.4% are large for gestational age (LGA, above the 90th percentile). On the contrary, of non-TT-homozygous neonates, 8.9% are SGA and 11.4% are LGA. TT-homozygosity is most common in SGA newborns (20.2%) and least common in those born LGA (8.6%, P adj < 0.01, Fig. 2b ).
Overall fTGH, which correlates negatively with maternal glycemic control during pregnancy, shows no relevant differences between genotypes. Nevertheless, AGT genotype distribution shows significant differences when grouped according to fTGH in newborns and this distribution is dependent on the cutoffs chosen. The higher the cutoff for fTGH in the newborns is chosen, the stronger, and the more significant, the differences in AGT genotype distribution become. Above fTGH of 6.5%, estimates of odds ratios for T-homozygosity in the groups with lower fTGH were found to range from 0.17 (fTGH < 7%) to 0.05 (fTGH < 7.5%; confidence interval (CI) [0.03; 0.84] and [0.005; 0.39]) with adjusted P-values decreasing concomitantly from P adj less than 0.05 to P adj less than 0.005 (significance of the decline in the odds ratios and P-values, P < 0.005 and < 0.01, respectively; Fig. 3 ).
Maternal age, smoking habits (smoking during pregnancy and amount of pack years smoked before pregnancy), APGAR score, BMI at beginning of pregnancy, history of hypertension or diabetes mellitus and prevalence of these conditions in the mother's family do not show any correlation with AGT genotype. Mothers of newborns homozygous for the ACE D allele have a higher prevalence of hypertensive disorders before and during
New evidence for the fetal insulin hypothesis Schlemm et al. 735 LGA, large for gestational age; SGA, small for gestational age. pregnancy (P < 0.01 and P < 0.05, respectively). ACE genotype in the newborn shows no significant correlation with birth weight, fTGH or any of the other parameters analyzed. An overview over the data can be found in Table 3 .
Discussion
We analyzed the relation between AGT and ACE polymorphisms in newborns and neonatal parameters such as birth weight, gestational age, fTGH and clinical data of the mother obtained from the maternity card (Mutterpass). We could show for the first time in a representative cohort of more than 1000 white women that the AGT TT genotype in newborns is significantly associated with lower birth weight. Furthermore, we detected a significant correlation between fTGH in the newborn and this genotype, suggesting a possible influence of AGT activity on the development of insulin resistance in utero. Odds ratio for angiotensinogen TT genotype in groups with lower fetal total glycated hemoglobin at different cutoffs. (a) Odds ratios (OR) for 3D fetal angiotensinogen genotype (fAGT) TT in the group with lower fetal total glycated hemoglobin (fTGH) value with 95% confidence intervals on logscale against fTGH cutoffs (%). Lower glycosylation is associated with relatively decreased probability of AGT T-homozygosity; higher glycosylation is associated with increased AGT T-homozygosity (cutoff fTGH < 7%: OR ¼ 0.168, P adj ¼ 0.044; cutoff fTGH < 7.5%: OR ¼ 0.051, P adj ¼ 0.003). (b) In the interval of fTGH 6% or more, our study demonstrated that the higher the cutoff chosen, the stronger the association between fTGH and AGT genotype (R ¼ À0.997, P < 0.005 for correlation cutoff $ OR, R ¼ À0.990, P < 0.01 for correlation cutoff $ P-value). ACE, angiotensin-converting enzyme; AGT, angiotensinogen; TGH, total glycated hemoglobin, HT (hist), history of hypertension; HT (preg), HT during pregnancy; HT (fam), HT in the woman's family, DM, diabetes mellitus;
LGA, large for gestational age; SGA, small for gestational age. Observational data of the study population according to AGT/ACE genotype. Mean AE SD. Tested for significant differences with student's t-test (birth weight), x 2 test/Fisher's exact test (dichotomous fTGH, smoking history, hypertension, diabetes mellitus) and Wilcoxon-Mann-Whitney-test (all others). P-values for gestational age, birth weight and fetal TGH are adjusted for birth weight/ gestational age, maternal age, BMI, smoking, fetal sex, maternal diabetes mellitus and maternal hypertension during pregnancy in an ANCOVA/binary logistic regression.
The ACE polymorphism does, by contrast, not correlate with aforementioned parameters.
The fetal programming hypothesis states that low birth weight in newborns may be partially related to maternal factors. Hattersley and Tooke [35, 40] , on the contrary, proposed the fetal insulin hypothesis. It states that insulin resistance is responsible for the cardiovascular diseases seen when the newborns have grown into adults; and that this insulin resistance is already present at birth and in utero, preventing insulin and insulin-like peptides to act as growth-mediating hormones. Low birth weight, adult insulin resistance, diabetes and CAD are all thought to be the result of the same insulin-resistant fetal genotype which by meaning is independent of environmental and maternal factors (e.g., nutrition status, metabolic disorders). Thus, low birth weight in newborns could reflect the presence of an insulin-resistant genotype in the fetus. Accordingly, much effort has been put into research trying to identify such fetal genotypes.
We demonstrated in a cohort of more than 1000 individuals that the AGT M235T polymorphism in newborns is associated with low birth weight and elevated fetal fTGH at birth. fTGH is a surrogate of fetal glycemic control and a possible marker for insulin resistance. It was previously shown in the same cohort to be significantly increased in newborns with low birth weight [34] . In our analysis, the correlation is strongest when fTGH values are highest.
The connection between the RAAS and insulin resistance is well known [41] . Patients under antihypertensive treatment with drugs affecting the RAAS such as ACE inhibitors and AT 1 receptor blockers have a lower incidence of new onset diabetes and show improved insulin sensitivity [42, 43] . From animal models, it is known that the application of AT 1 receptor blockers improves glucose tolerance through enhancement of insulin mediated glucose uptake in peripheral organs (e.g., skeletal muscle), possibly due to changes in blood flow [44] . Also, changes in muscle fiber composition, decreased tumor necrosis factor (TNFa) concentrations in skeletal muscle tissue and crosstalk in the signaling pathways of AGT and insulin receptors are discussed to explain the observed phenomena [41, 44] . It was also shown that adults homozygous for the T allele have a higher risk of developing CAD and diabetic nephropathy [30, 45] . The correlation between AGT T-homozygosity and fTGH was, however, only seen in infants with increased fTGH, suggesting further mechanisms playing a role and mediating the influence of the AGT polymorphism on fetal growth.
The maternal RAAS system plays an important role in the nutrient supply of the fetus by regulating the blood flow in the spiral arteries of the placenta. All the components of the vascular RAAS are expressed in and around spiral arteries [13, 14, 27] . During pregnancy, spiral arteries undergo remodeling into dilated uteroplacental vessels through mechanisms mostly unknown to date. AGT TT polymorphism is associated with abnormal spiral artery remodeling thereby affecting vascular resistance [21] . Elevated local concentrations of AGT II may cause medial hyperplasia and/or angiogenesis in remodeling spiral arteries [14] . The placental vascular bed including the spiral and umbilical arteries is, however, not only of maternal but also of fetal origin [46] . Mutations of constituents of the fetal RAAS system causing a higher activity could therefore induce impairment in the development of the placental vascular bed and consequently lead to a decreased oxygen and energy supply and thus to fetal growth restriction [32, 33] . Activated fetal RAAS represented by the AGT M235T polymorphism might therefore exert its influence on birth weight not only by causing insulin resistance in utero, but possibly also by modification of placental vascular remodeling and other mechanisms not yet understood.
ACE genotype distribution in the newborns and birth weight did not correlate significantly, confirming findings by Uma et al. [47] in an analysis of a much smaller cohort than ours. Nevertheless, newborns carrying the ACE DD genotype in our cohort tend to have a lower birth weight and this trend was described before [48] . Although existent, the influence of the ACE polymorphism might be too small to be easily detected. Although ACE I/D polymorphism is associated with higher ACE plasma levels, it has not been shown to increase the risk to develop hypertension [49, 50] . The changes caused by the I/D polymorphism might therefore not be strong enough to cause easily detectable physiological changes and analyses in even larger cohorts are necessary to readdress this question. In contrast, meta-analyses, casecontrol studies and animal experiments have shown the AGT M235T polymorphism to be related to higher AGT levels and an increased risk of hypertension [51, 52] . The AGT M235T polymorphism might therefore be of higher functional relevance in modifying RAAS activity. This could explain the association of low birth weight with the AGT but not the ACE polymorphism seen in our study.
Looking at the results of our analyses, limitations inherent to our study have to be mentioned. The newborn's fTGH was measured via an HPLC-based method assuming that elevated fetal blood glucose concentrations result in a higher percentage of glycosylated fTGH in the newborn. Other standard methods directly measuring insulin sensitivity have to date not been validated in newborns mostly because they are highly invasive and therefore unethical in healthy newborns. Neither did we measure plasma levels of constituents of the RAAS. Our data suggest the proposition of the hypothesis presented and discussed in the present study; nevertheless, future studies in independent cohorts conforming our findings are necessary before more definitive conclusions can be drawn.
In conclusion, we showed that the AGT M235T polymorphism in newborns is associated with low birth weight. This might be due to impaired vascular remodeling and consequent decreased uteroplacental blood flow. Additionally, our analysis suggests that effects of AGT on insulin resistance might play an important role in the development of low birth weight. Our findings give support to the fetal insulin hypothesis and the idea that fetal genotypes could be important determinants of fetal growth and metabolic programming. The AGT M235T polymorphism might, among other candidates, represent one of the linking factors between the RAAS and insulin resistance with effects present already in utero and in newborns. Insulin resistance in utero could be one explanation for low birth weight with increased odds of suffering from adverse cardiovascular events later in life.
